.webp)
In the past decade, the way type 2 diabetes and kidney problems are treated in North America has changed a lot. And a major reason behind this shift is a group of medicines called SGLT2 inhibitors. These medicines help lower blood sugar. They also protect the heart and kidneys.
Want to learn more about how SGLT2 inhibitors work? And what are the top SGLT2 inhibitors in North America? Our detailed blog on the North America SGLT2 inhibitors market covers everything in detail.
What Are SGLT2 Inhibitors?
SGLT2 inhibitors are medicines that help the body get rid of extra sugar through urine. Normally, sugar from the blood is returned to the body after the kidneys filter it. These medicines block that step. So, extra sugar leaves the body naturally. This helps control blood sugar without putting much stress on the body.
Inhibitors from the SGLT2 inhibitors market have more to them than managing sugar levels. Early research suggests that people taking these medicines also have better heart and kidney health. As such, SGLT2 inhibitors are now used to treat more than just diabetes.
These inhibitors are easy to take and work in a simple way. Additionally, their various health benefits make them a popular choice for many healthcare providers.
What Are Indications of SGLT2 Inhibitors?
Type 2 Diabetes
SGLT2 inhibitors were originally developed to help people with Type 2 diabetes control their blood sugar. These inhibitors work by removing extra sugar through urine. They are useful for people who still have high blood sugar after using other diabetes medicines. Individuals taking these inhibitors may also experience slight weight loss and a small drop in blood pressure.
Heart Failure
SGLT2 inhibitors from the North America SGLT2 inhibitors market are now widely used for heart failure. Heart failure is a condition where the heart can’t pump blood in a proper way. Doctors like using them as they help the body remove extra fluid and make breathing easier. They also reduce pressure on the heart. Patients taking these medications often experience less chest discomfort and reduced shortness of breath.
Chronic Kidney Disease
SGLT2 inhibitors help protect the kidneys. And this is especially the case with people who have diabetes. SGLT2 inhibitors slow the damage caused by high sugar levels to the kidneys over time. They work by reducing stress on the kidneys. SGLT2 inhibitors also reduce protein loss in urine and help the kidneys function better in the long term.
What’s the North America SGLT2 Inhibitors Market Outlook?
Our assessment reveals the North America SGLT2 inhibitors market to account for sustained growth. The market was valued at USD 7.32 billion in 2024. It is projected to account for a CAGR of 8.4% during the forecast period, 2025 to 2034.
The elevated body fat due to obesity significantly increases the risk of developing Type 2 diabetes. This, in turn, is driving the demand for effective glucose-lowering therapies like SGLT2 inhibitors. The market is also benefiting from the rising innovation and marketing by pharmaceutical companies.
Which SGLT2 Inhibitors Are Commonly Used in North America?
Empagliflozin
Empagliflozin is a widely used SGLT2 inhibitor in North America. It works well for Type 2 diabetes and heart problems. It helps lower blood sugar and supports weight loss. It also improves heart health. Many doctors choose Empagliflozin for people who have both diabetes and heart disease. It’s also used in patients with heart failure.
Dapagliflozin
Dapagliflozin is popular because it helps in several conditions. These include Type 2 diabetes, heart failure, and chronic kidney disease. It is known to protect the kidneys and slow down kidney damage. This makes it a top choice for individuals with diabetes and kidney issues. It also reduces the chances of hospital visits due to heart failure.
Canagliflozin
Canagliflozin was the first SGLT2 inhibitor approved in the U.S. It’s still widely used to control blood sugar and protect the kidneys. Studies show it helps lower the risk of serious kidney problems in people with diabetes. It also supports heart health. This makes it suitable for individuals who need blood sugar control and cardiovascular protection.
Ertugliflozin
Ertugliflozin is another option for Type 2 diabetes. The SGLT2 inhibitor is somewhat less well-known. But it works similarly to others. Doctors sometimes opt for it as it's affordable and easy to access. It’s simple to use once a day and supports weight loss. Ertugliflozin is also available in combination with other medicines from the diabetes drug market.
Sotagliflozin
Sotagliflozin is newer compared to others. The medicine works in two ways. It helps remove sugar through the kidneys and also slows sugar absorption in the gut. In North America, Sotagliflozin is mainly used for heart failure. It helps reduce hospital visits. It’s seen as a promising option for people with heart-related conditions.
What’s New in the Market?
FDA Approval of Farxiga for Children with Type-2 Diabetes
In June 2024, AstraZeneca received FDA approval to use Farxiga (dapagliflozin) in children aged 10 and above with Type 2 diabetes. This is a major step, as treatment options for younger patients are quite limited.
The approval was based on strong results from the Phase III T2NOW trial. The trial showed that Farxiga helped lower A1C levels much more than a placebo. Nearly 30,000 children in the U.S. are already living with Type 2 diabetes. This decision gives doctors a new and convenient option to help manage the condition.
Safety findings in children were similar to those seen in adults. As such, healthcare providers have greater confidence in prescribing Farxiga for younger patients.
Conclusion
SGLT2 inhibitors have changed the way doctors treat Type 2 diabetes and heart problems in North America. These medicines work in a simple way and offer many benefits. They are also supported by strong research. As such, they have become an important treatment option for many patients. With new studies coming out and more people learning about these medicines, the SGLT2 inhibitors market in North America will continue to be an important part of healthcare in North America.
.png)
